

CITATION REPORT

List of articles citing

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

DOI: 10.1007/s12072-017-9799-9

Hepatology International, 2017, 11, 317-370.

Source: <https://exaly.com/paper-pdf/66370443/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1271	Nurse-led surveillance for liver cancer in stable cirrhosis. 2017 , 15, S12-S14		
1270	The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. 2017 , 2, 72		16
1269	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. 2017 , 6, 387-396		43
1268	Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): A Surveillance, End Results and Epidemiology (SEER) database analysis. 2018 , 41, 551-561		14
1267	Anethum graveolens (dill) - A medicinal herb induces apoptosis and cell cycle arrest in HepG2 cell line. 2018 , 219, 15-22		15
1266	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. 2018 , 47, 1201-1212		11
1265	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. 2018 , 53, 734-740		21
1264	Current topics in the surgical treatments for hepatocellular carcinoma. 2018 , 2, 137-146		18
1263	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. 2018 , 7, 104-119		57
1262	LI-RADS 2017: An update. 2018 , 47, 1459-1474		27
1261	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. 2018 , 38, 1459-1467		21
1260	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. 2018 , 16, 765-773.e2		29
1259	Metastatic hepatocellular carcinoma mimicking acute dacryocystitis. 2018 , 53, e132-e134		4
1258	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. 2018 , 68, 724-732		68
1257	Liver-directed therapy for hepatocellular carcinoma. 2018 , 43, 203-217		8
1256	Comparison of hepatitis E virus seroprevalence between HBsAg-positive population and healthy controls in Shandong province, China. 2018 , 18, 75		6
1255	Chronic Hepatitis B Infection: A Review. 2018 , 319, 1802-1813		266

1254	Imaging Tiny Hepatic Tumor Xenografts via Endoglin-Targeted Paramagnetic/Optical Nanoprobe. 2018 , 10, 17047-17057	22
1253	Synergistic effect of oral corticosteroids use on risk of hepatocellular carcinoma in high risk populations. 2018 , 52, 73-77	4
1252	Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. 2018 , 14, 1701-1710	19
1251	Outcomes of resection surgery for hepatocellular carcinoma: Does size matter?. 2018 , 81, 89-91	3
1250	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. 2018 , 36, 332-339	33
1249	Should we undertake surveillance for HCC in patients with NAFLD?. 2018 , 68, 326-334	93
1248	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. 2018 , 16, 163-170	17
1247	HCC with low- and normal-serum alpha-fetoprotein levels. 2018 , 15, 453-464	29
1246	Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. 2018 , 24, 4000-4013	39
1245	Laparoscopic liver resection in patients with liver cirrhosis-the path towards standard of care. 2018 , 7, 68-69	1
1244	Searching for common ground in a global disease. 2018 , 7, 297-299	0
1243	Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. 2018 , 3, 104	
1242	Systemic Therapy for Hepatocellular Carcinoma: Recent Advances. 2018 , 59, 587-603	3
1241	Eye Opener to EtOH Ablation for Juxta-Cardiac Hepatocellular Carcinoma. 2019 , 5, 109-116	3
1240	Hepatocellular carcinoma: one world, one cancer-different guidelines?. 2018 , 7, 41-43	4
1239	Investigation of the clinical significance and molecular mechanism of miR-21-5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation. 2019 , 17, 230-246	8
1238	Diagnostic Algorithm of Hepatocellular Carcinoma: Classics and Innovations in Radiology and Pathology. 2018 ,	1
1237	Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. 2018 , 38,	1

1236	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. <i>Hepatology International</i> , 2018 , 12, 544-551	8.8	7
1235	Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. 2018 , 53, 1575-1583		12
1234	Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. 2018 , 7, 353-371		38
1233	Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study. 2018 , 38, 2239-2247		24
1232	Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. 2018 , 18, 915		21
1231	Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. 2018 , 209, 348-354		22
1230	Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients. 2018 , 2018, 7897346		67
1229	Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. 2018 , 24, 2348-2362		59
1228	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. 2018 , 8, 15821		2
1227	Hepatocellular carcinoma: Where are we in 2018?. 2018 , 55, 450-503		1
1226	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. 2018 , 113, 1629-1638		17
1225	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. 2018 , 13, e0202650		11
1224	Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. 2018 , 6, 110-120		21
1223	MicroRNA-520a suppresses HBV replication in HepG2.2.15 cells by inactivating AKT. 2018 , 46, 4693-4704		6
1222	Should We Abandon Current Hepatocellular Carcinoma Screening Practices?. 2018 , 155, 972-974		7
1221	Polymorphisms in the 3'-UTR of SCD5 gene are associated with hepatocellular carcinoma in Korean population. 2018 , 45, 1705-1714		2
1220	Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. 2018 , 10, 2695-2709		20
1219	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. 2018 , 155, 1128-1139.e6		53

1218	Value of α -fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. 2018 , 15, 8863-8870	12
1217	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. 2018 , 8, 9997	31
1216	PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway. 2018 , 47, 1643-1654	19
1215	Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. 2018 , 9, 2380-2388	11
1214	Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. 2018 , 18, 643	5
1213	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. 2018 , 38, 242-251	51
1212	Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. 2018 , 2018, 4756147	49
1211	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. 2018 , 47, 585-602	17
1210	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. 2018 , 25, 1608-1616	3
1209	Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. 2018 , 8, 12787	8
1208	Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma. 2018 , 2018, 5859415	17
1207	Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. 2018 , 9, 189-197	29
1206	Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. 2018 , 23, 235-242	18
1205	Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. 2018 , 2018, 7465126	8
1204	Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis. 2018 , 10,	23
1203	Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion. 2018 , 105, 683-689	12
1202	Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. 2018 , 13, e0190261	4
1201	Regorafenib: A Review in Hepatocellular Carcinoma. 2018 , 78, 951-958	21

1200	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. 2019 , 8, 121-129	88
1199	Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. 2019 , 217, 739-744	28
1198	Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. 2019 , 44, 493-508	8
1197	The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction. 2019 , 8, 298-300	2
1196	Status of, and strategies for improving, adherence to HCC screening and surveillance. 2019 , 6, 131-141	12
1195	Ablation in Primary Liver Tumors. 2019 , 03, 107-116	
1194	Biomarkers imaging in the early detection of hepatocellular carcinoma and prognosis. 2019 , 7, 1367-1382	15
1193	Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA. 2019 , 33, e22999	15
1192	Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. 2019 , 19, 795	26
1191	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. 2019 , 39, 2214-2229	116
1190	B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. 2019 , 8, 271-280	25
1189	Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. 2019 , 20, 2823-2831	20
1188	A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. 2019 , 14, 137	15
1187	Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. 2019 , 20, 1019-1041	16
1186	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. 2019 , 11,	92
1185	Hepatocellular Carcinoma. 2019 ,	1
1184	Clinical performance of α -L-fucosidase for early detection of hepatocellular carcinoma. 2019 , 13, 545-555	12
1183	Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. 2019 , 84, 809-817	12

1182	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. 2019 , 4, 721-730	46
1181	Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. 2019 , 8, 5097-5107	5
1180	Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. 2019 , 43, 2894-2901	5
1179	Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model. 2019 , 11, 5523-5529	1
1178	Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. 2019 , 26, 1372-1376	
1177	Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma \leq 5 cm: A propensity score-matched analysis. 2019 , 166, 254-262	16
1176	Growing burden of alcoholic liver disease in China: A review. 2019 , 25, 1445-1456	32
1175	Enhancing early stage of hepatocellular carcinoma: Does correlate to MicroRNA 122 and miR196a interaction?. 2019 ,	
1174	Laparoscopic hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. 2019 , 11, 5711-5724	9
1173	Comparison of the current international guidelines on the management of HCC. 2019 , 1, 114-119	15
1172	Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma. 2019 , 39, 3909-3916	12
1171	Ethnic Differences in Labour Market Outcomes—the Role of Language-Based Discrimination. 2019 ,	2
1170	Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. 2019 , 8,	11
1169	Safety and efficacy of microwave ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile ducts through a percutaneous transhepatic cholangial drainage tube. 2019 , 2, 84-90	
1168	Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. 2019 , 2, 91-96	2
1167	The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system. 2019 , 120, 108685	20
1166	A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma. 2019 , 9, 1503-1515 ³⁴	
1165	Commentary on: "Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - a retrospective cohort study". 2019 , 71, 168	

1164	Clinical predictors of small solitary hepatitis B virus-related hepatocellular carcinoma microinvasion. 2019 , 89, E438-E442		
1163	Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. 2019 , 8, 6614-6623		5
1162	Research on the Adsorption Behaviour of Crystal Violet Simulated Wastewater on Fallen Willow Leaves. 2019 , 267, 032092		0
1161	CNN-Based Macropixel-Level Up-Sampling for Plenoptic Image Coding. 2019 , 7, 80020-80026		1
1160	Photomedicine Lights Up the Future of Fighting Cancer. 2018 , 18, 1533033819852971		
1159	Contrast-enhanced ultrasonography: is it an ideal tool for hepatocellular carcinoma surveillance?. 2019 , 9, 1611-1614		2
1158	A Novel and Accurate Method for Moisture Adsorption Isotherm Determination of Sultana Raisins. 2019 , 12, 2491-2499		2
1157	Unsteady numerical simulation on helium cooldown process for the 650 MHz two-cell superconducting cavity. 2019 , 3, 1		1
1156	Efficient scheduling for multi-stage coflows. 2019 , 2, 83-97		
1155	Local application of doxorubicin- loaded Iron oxid nanoparticles and the vascular disrupting agent via the hepatic artery: chemoembolization-photothermal ablation treatment of hepatocellular carcinoma in rats. 2019 , 19, 71		8
1154	Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. 2019 , 11,		25
1153	Sequential drug delivery for liver diseases. 2019 , 149-150, 72-84		4
1152	Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?. 2019 , 8, 148-150		0
1151	Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. 2019 , 11, 8799-8806		13
1150	Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. 2019 , 13, 1077-1088		2
1149	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019 , 13, 587-598	8.8	22
1148	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. 2019 , 42, 1563-1570		7
1147	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. 2019 , 3, 302-310		17

1146	A Prospective Assessment of the Diagnostic Value of Contrast-Enhanced Ultrasound, Dynamic Computed Tomography and Magnetic Resonance Imaging for Patients with Small Liver Tumors. 2019 , 8,		8
1145	The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, August 29-31, 2019. 2019 , 8, 1-204		78
1144	High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank. 2019 , 9, 12186		4
1143	Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer. 2019 , 18, 4176-4184		13
1142	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019 , 13, 649-661	8.8	36
1141	Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. 2019 , 37, 781-792		4
1140	Can contrast-enhanced ultrasound with perfluorobutane add value in detection of hepatocellular carcinoma in cirrhosis during surveillance?. 2019 , 9, 1466-1469		
1139	Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. 2019 , 9, 625-651		4
1138	Arctigenin Attenuates Tumor Metastasis Through Inhibiting Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Suppressing GSK3 β -Dependent Wnt/ β Catenin Signaling Pathway and. 2019 , 10, 937		12
1137	Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. 2019 , 14, e0222605		7
1136	The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. <i>Hepatology International</i> , 2019 , 13, 199-204	8.8	23
1135	A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma. 2019 , 8, 373-386		78
1134	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. 2019 , 6, 23-30		9
1133	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. 2019 , 71, 523-533		57
1132	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. 2019 , 13, 615-621		3
1131	Systemic Treatment Options in Hepatocellular Carcinoma. 2019 , 8, 427-446		52
1130	A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals. 2019 , 6, e1614419		0
1129	Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1 β -mediated epithelial-mesenchymal transition. 2019 , 137, 32-44		10

1128	Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. 2019 , 8,	10
1127	Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. 2019 , 20, 863-879	14
1126	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. 2019 , 39, 1478-1489	27
1125	The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. 2019 , 19, 497	5
1124	Identification and integrative analysis of microRNAs and mRNAs involved in proliferation and invasion of pressure-treated human liver cancer cell lines. 2019 , 20, 375-387	6
1123	A critical appraisal of the use of ultrasound in hepatic steatosis. 2019 , 13, 667-681	23
1122	Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection. 2019 , 495, 309-317	8
1121	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. 2019 , 9, e026703	15
1120	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. 2019 , 34, 2179-2186	1
1119	Role of US LI-RADS in the LI-RADS Algorithm. 2019 , 39, 690-708	25
1118	The association of liver function and quality of life of patients with liver cancer. 2019 , 19, 66	11
1117	Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. 2019 , 17, 75	4
1116	Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. 2019 , 62, 152930	55
1115	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. 2019 , 42, 1262-1270	2
1114	Microfluidic chip combined with magnetic-activated cell sorting technology for tumor antigen-independent sorting of circulating hepatocellular carcinoma cells. 2019 , 7, e6681	8
1113	Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. 2019 , 157, 54-64	156
1112	High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. 2019 , 49, 1046-1053	16
1111	Student Conference Abstracts. 2019 , 66, 101-113	78

1110	Pegylated interferon- α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155. 2019 , 18, 494-500	2
1109	New treatment-induced adverse effects we need to learn as modern hepatologists. <i>Hepatology International</i> , 2019 , 13, 391-394	8.8
1108	Lenvatinib: A Review in Hepatocellular Carcinoma. 2019 , 79, 665-674	63
1107	MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3. 2019 , 27, 449-458	19
1106	Downregulation of PHF6 Inhibits Cell Proliferation and Migration in Hepatocellular Carcinoma. 2019 , 34, 245-251	5
1105	Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma. 2019 , 11, 1401-1414	23
1104	Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. 2019 , 64, 993-1000	12
1103	Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. 2019 , 49, 1405-1411	7
1102	Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. 2019 , 9, 1426-1452	45
1101	Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI. 2019 , 44, 2366-2376	4
1100	Ultrasound Screening and Surveillance in Hepatocellular Carcinoma. 2019 , 7, 1	
1099	Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. 2019 , 9, 3236	1
1098	FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma. 2019 , 39,	7
1097	GI Surgery Annual. 2019 ,	0
1096	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. 2019 , 116, 6308-6312	72
1095	Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. 2019 , 22, 363-370	4
1094	Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. 2019 , 70, 1133-1144	212
1093	Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images. 2019 , 19, 23	41

1092	Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. 2019 , 39, 163-177	24
1091	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. 2019 , 25, 789-807	91
1090	I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. 2019 , 18, 521-529	15
1089	Hepatocellular Carcinoma. 2019 , 380, 1450-1462	1441
1088	I seeds implantation for treating residual hepatocellular carcinoma located beneath the diaphragm after transcatheter arterial chemoembolization. 2019 , 18, 420-425	4
1087	Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. 2019 , 20, 385-398	19
1086	Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. 2019 , 64, 934-950	27
1085	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. 2019 , 8, 312-325	37
1084	Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. 2019 , 11, 1013-1021	5
1083	A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. 2019 , 18, 28	215
1082	Abstracts. 2019 , 39, 2420-2468	
1081	Thermal ablation for hepatocellular carcinoma: what's new in 2019. 2019 , 8, 58	25
1080	Does artificial ascites induce heat sink effect or electricity steal effect in the radiofrequency ablation of superficial liver tumor?. 2019 , 6, 141-143	
1079	Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. 2019 , 20, 1616-1626	16
1078	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. 2019 ,	5
1077	Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. 2019 , 10, 4892-4901	11
1076	Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. 2019 ,	5
1075	CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. 2019 , 2019, 1245072	36

1074	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. 2019,	3
1073	Recent advances in multiphoton microscopy combined with nanomaterials in the field of disease evolution and clinical applications to liver cancer. 2019, 11, 19619-19635	14
1072	Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma: An updated meta-analysis. 2019, 98, e16725	7
1071	Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. 2019, 1, e190010	15
1070	A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. 2019, 8, 299-311	39
1069	Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. 2019, 8,	8
1068	The Defective Allele of Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma. 2019, 10, 5735-5743	5
1067	Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. 2019, 98, e16150	3
1066	The outcome of the HCC patients underwent ALPPS: Retrospective study. 2019, 98, e17182	3
1065	Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. 2019, 98, e18366	4
1064	Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. 2019, 31, 865-872	20
1063	Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies. 2019, 69, 648-654	2
1062	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. 2019, 82, 2-10	11
1061	Hepatocellular carcinoma in the noncirrhotic liver: a literature review. 2019, 31, 743-748	9
1060	Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. 2019, 54, 494-499	9
1059	Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. 2019, 8, 447-456	18
1058	Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. 2019, 19, 84	17
1057	Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma. 2019, 11, 9863-9869	4

1056	Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. 2019 , 8, 186-202		10
1055	Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. 2019 , 8, 78-91		27
1054	Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward. 2019 , 70, 567-568		2
1053	Goals and targets for personalized therapy for HCC. <i>Hepatology International</i> , 2019 , 13, 125-137	8.8	167
1052	Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. 2019 , 92, 20180701		0
1051	New generation cancer therapy: right direction for sure with some uncertainty. <i>Hepatology International</i> , 2019 , 13, 22-24	8.8	
1050	Gadoxetic acid-enhanced dynamic magnetic resonance imaging using optimized integrated combination of compressed sensing and parallel imaging technique. 2019 , 57, 111-117		10
1049	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. 2019 , 28, 531-538		64
1048	Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. 2019 , 78, 130-139		5
1047	Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. 2019 , 44, 1141-1151		13
1046	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019 , 13, 248-252	8.8	25
1045	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. 2019 , 13, 179-187		26
1044	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. 2019 , 15, 439-449		0
1043	Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. 2019 , 50, 888-893		1
1042	Recent advances in medical management of hepatocellular carcinoma. 2019 , 49, 14-32		41
1041	Analgesic-antitumor peptide inhibits angiogenesis by suppressing AKT activation in hepatocellular carcinoma. 2019 , 455, 119-125		3
1040	Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?. 2019 , 39, 43-52		7
1039	A new microwave applicator for laparoscopic and robotic liver resection. 2019 , 36, 75-86		6

1038	Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis. 2019 , 44, 539-548	39
1037	Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?. 2019 , 29, 1724-1732	53
1036	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. 2020 , 271, 534-541	41
1035	Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. 2020 , 24, 50-57	12
1034	Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. 2020 , 22, 370-380	16
1033	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. 2020 , 38, 172-180	36
1032	Predicting Patients With Insufficient Liver Enhancement in the Hepatobiliary Phase Before the Injection of Gadoxetic Acid: A Practical Approach Using the Bayesian Method. 2020 , 51, 62-69	1
1031	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. 2020 , 119, 610-620	7
1030	Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. 2020 , 38, 5-24	6
1029	Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. 2020 , 30, 370-382	32
1028	Cancer in the Tropics. 2020 , 178-188	
1027	Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. 2020 , 50, 67-74	6
1026	Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosis-Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrast-Enhanced MRI. 2020 , 51, 812-823	6
1025	Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. 2020 , 30, 413-424	59
1024	The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management. 2020 , 51, 829-835	
1023	Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma. 2020 , 51, 1755-1763	6
1022	Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma. 2020 , 50, 36-43	3
1021	Budd-Chiari Syndrome. 2020 ,	0

1020	Cirrhotic Nodule Transformation to Hepatocellular Carcinoma: Natural History and Predictive Biomarkers on Contrast-Enhanced Ultrasound. 2020 , 214, 96-104	0
1019	Impact of overweightness and critical weight loss on overall survival in patients with hepatocellular carcinoma initially treated with chemoembolization. 2020 , 8, 125-133	2
1018	Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma. 2020 , 43, 587-596	
1017	The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. 2020 , 34, e23200	8
1016	Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. 2020 , 30, 2302-2311	9
1015	Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. 2020 , 18, 2091-2100.e7	13
1014	Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. 2020 , 72, 937-945	22
1013	Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. 2020 , 9, 1349-1364	19
1012	Urine Fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma. 2020 , 318, G305-G312	11
1011	Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis. 2020 , 22, 595-602	0
1010	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. 2020 , 69, 1492-1501	164
1009	Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center. 2020 , 51, 972-979	0
1008	Hepatocyte-Specific Magnetic Resonance Imaging-Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis. 2020 , 26, 359-369	0
1007	LncRNA SNHG15: A new budding star in human cancers. 2020 , 53, e12716	28
1006	Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. 2020 , 30, 1624-1633	2
1005	A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI. 2020 , 32, 74-79	
1004	Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. 2020 , 32, 406-419	9
1003	Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. 2020 , 32, 517-523	6

1002	Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. 2020 , 43, 572-586	6
1001	Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. 2020 , 9, 41-49	15
1000	Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. 2020 , 9, 50-62	24
999	Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. 2020 , 12,	9
998	Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How?. 2020 , 24, 623-636	6
997	Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines. 2020 , 22, 1206-1215	0
996	Pure laparoscopic versus open major hepatectomy for hepatocellular carcinoma with liver F4 cirrhosis without routine Pringle maneuver - A propensity analysis in a single center. 2020 , 35, 315-320	5
995	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. 2020 ,	1
994	Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. 2020 , 24, 577-590	10
993	Role of External Beam Radiotherapy in Hepatocellular Carcinoma. 2020 , 24, 701-717	5
992	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. 2020 , 9, 596-612	7
991	TNFRSF12A and a new prognostic model identified from methylation combined with expression profiles to predict overall survival in hepatocellular carcinoma.. 2020 , 9, 5493-5507	0
990	Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. 2020 , 68, 169-174	1
989	Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. 2020 , 13, 10267-10273	4
988	Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. 2020 , 48, 300060520961260	0
987	Enhancement patterns of small hepatocellular carcinoma (≤30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. 2020 , 132, 109341	3
986	Non-Alcoholic Fatty Liver Disease. 2020 ,	1
985	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020 , 14, 889-919 ^{8.8}	142

984	LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. 2020 , 10, 7527-7544	16
983	Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. 2020 , 21,	6
982	Advances in the early diagnosis of hepatocellular carcinoma. 2020 , 7, 308-319	35
981	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. 2020 , 9, 382-396	24
980	Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma. 2020 , 12,	1
979	OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. 2020 , 92, 3596	18
978	What is the difference in ablation zone of multi-bipolar radiofrequency ablation between liver cirrhosis and normal liver background? - a prospective clinical study. 2020 , 37, 1248-1259	4
977	Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy. 2020 , 8, 1282	1
976	Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. 2020 , 7, 301-313	8
975	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. 2021 , 224, 294-302	10
974	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. 2020 , 9,	4
973	Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis. 2020 ,	6
972	The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. 2020 , 12, 12077-12086	2
971	Gene Methylation as a Noninvasive Marker for Hepatocellular Carcinoma. 2020 , 2020, 6289063	6
970	Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. 2020 , 2020, 8826091	3
969	Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk. 2020 , 297, 108-116	9
968	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. 2020 , 9, 452-463	87
967	Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. 2020 , 168, 643-652	13

966	Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. 2020 , 36, 43	3
965	Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. 2020 , 10, 4607	0
964	What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. 2020 , 22, 105	8
963	Hepatocellular Carcinoma: Eastern Experience. 2020 , 119-144	
962	Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. 2021 , 28, 1464-1476	5
961	Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. 2020 , 12, 5461-5468	5
960	Liver Imaging Reporting and Data System: Current Challenges and Future Directions. 2020 , 2, 151-163	1
959	Emerging Evidence of the Utility of Perfluorobutane-enhanced US as a Diagnostic Test for Hepatocellular Carcinoma. 2020 , 297, 117-119	0
958	Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: Initial experience and findings. 2020 , 12, 233-240	2
957	Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. 2020 , 8, 870	10
956	Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. 2020 , 99, e21454	3
955	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. 2020 , 2, 100173	10
954	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. 2020 , 9, 503-517	8
953	Four Autophagy-Related lncRNAs Predict the Prognosis of HCC through Coexpression and ceRNA Mechanism. 2020 , 2020, 3801748	15
952	New advances in the diagnosis and management of hepatocellular carcinoma. 2020 , 371, m3544	74
951	Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. 2020 , 37, 1149-1158	3
950	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. 2020 , 8,	18
949	A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma. 2020 , 59, 1243-1255	1

948	Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. 2020 , 21, 650-663	3
947	GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. 2020 , 40, 2828-2833	16
946	Relevance Function of Linc-ROR in the Pathogenesis of Cancer. 2020 , 8, 696	16
945	The Importance of AFP in Liver Transplantation for HCC. 2020 , 51, 1127-1132	10
944	Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. 2020 , 65, 3456-3462	7
943	Pediatric Hepatocellular Carcinoma. 2020 , 51, 1169-1175	6
942	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. 2020 , 20, 251	5
941	Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization , pharmacokinetics and tumor response. 2020 , 27, 1301-1307	7
940	Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. 2020 , 99, e21387	1
939	Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. 2020 , 21,	5
938	Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. 2020 , 7, 107-116	7
937	Prediction of microvascular invasion of hepatocellular carcinoma: value of volumetric iodine quantification using preoperative dual-energy computed tomography. 2020 , 20, 60	2
936	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. 2020 , 122, 1587-1594	4
935	Adherence to Hepatocellular Carcinoma Surveillance and Perceived Barriers Among High-Risk Chronic Liver Disease Patients in Yunnan, China. 2020 , 12, 6209-6220	4
934	Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. 2020 , 10, 525461	7
933	Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. 2020 , 10,	22
932	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020 , 14, 1023-1033	8.8 10
931	The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. 2020 , 8, 1402	1

930	Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. 2020 , 10, 561669		4
929	A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. 2020 , 9, 717-728		4
928	Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma. 2020 , 13, 12341-12355		2
927	Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. 2020 , 10, 562103		3
926	Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. 2020 , 8,		18
925	Limitations of the Barcelona clinic liver cancer staging treatment strategy in hepatocellular carcinoma patients with performance status 1. 2020 , 8, 1042		1
924	Management of patients with intermediate stage hepatocellular carcinoma. 2020 , 12, 1758835920970840		9
923	Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. 2020 , 7, 219-232		6
922	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. 2020 , 12,		7
921	Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. <i>Hepatology International</i> , 2020 , 14, 1009-1022	8.8	4
920	Transcholecystic Contrast-Enhanced Ultrasound-Guided Percutaneous Transhepatic Biliary Drainage for Central Bile Duct Protection During Thermal Tumor Ablation. 2020 , 31, 1587-1591		1
919	Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. 2020 , 7, 233-256		0
918	Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma. 2020 , 17, 2888-2894		
917	APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. <i>Hepatology International</i> , 2020 , 14, 920-929	8.8	10
916	Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. 2020 , 9, 663-681		6
915	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. 2020 , 27, 932-940		1
914	Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute. 2020 , 7, 100219		2
913	A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. 2020 , 8, 3485-3499		15

912	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. 2020 , 9, 245-260	63
911	Effect and Mechanism of miR-26a-5p on Proliferation and Apoptosis of Hepatocellular Carcinoma Cells. 2020 , 12, 3013-3022	5
910	Characterization of Early Hepatocellular Carcinoma and High-Grade Dysplastic Nodules on Contrast-Enhanced Ultrasound: Correlation With Histopathologic Findings. 2020 , 39, 1799-1808	4
909	Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. 2020 , 46, 1703-1710	4
908	The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. 2020 , 30, 5650-5662	2
907	Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?. 2020 , 73, 467-468	1
906	Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. 2020 , 7,	0
905	Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC. 2020 , 21, 102-105	4
904	Effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells: A protocol of systematic review and meta-analysis. 2020 , 99, e20290	
903	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. 2020 , 24, 415-423	1
902	Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. 2020 , 48, 300060520930151	8
901	Progress and prospects of biomarkers in primary liver cancer (Review). 2020 , 57, 54-66	13
900	ACR Appropriateness Criteria [®] Chronic Liver Disease. 2020 , 17, S70-S80	2
899	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. 2020 , 9,	59
898	Influence of tube voltage, tube current and newer iterative reconstruction algorithms in CT perfusion imaging in rabbit liver VX2 tumors. 2020 , 26, 264-270	
897	Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. <i>Hepatology International</i> , 2020 , 14, 544-555	8.8 3
896	Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference?. 2020 , 37, 688-695	3
895	New frontiers in liver resection for hepatocellular carcinoma. 2020 , 2, 100134	14

894	Molecular Imaging and Therapy of Liver Tumors. 2020 , 50, 419-433	1
893	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. 2020 , 40, 2522-2534	10
892	Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. 2020 , 10, 680	46
891	Thermal ablation—An option in curative treatment of HCC. 2020 , 13, 207-211	0
890	Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation. 2021 , 36, 820-826	2
889	Characterization of Indeterminate Liver Lesions on CT and MRI With Contrast-Enhanced Ultrasound: What Is the Evidence?. 2020 , 214, 1295-1304	17
888	The Changing Epidemiology of Hepatocellular Carcinoma : Experience of a Single Center. 2020 , 2020, 5309307	7
887	Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2020 , 9, 138-147	5
886	Adjuvant I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. 2020 , 5, 548-560	15
885	Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. 2020 , 30, 4150-4163	13
884	Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. 2020 , 9, 3057-3069	12
883	Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Initial Application of a Radiomic Algorithm Based on Grayscale Ultrasound Images. 2020 , 10, 353	21
882	Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. 2020 , 12, 1693-1712	11
881	Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol. 2020 , 45, 2688-2697	17
880	Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer. 2020 , 2020, 6076572	4
879	Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. 2020 , 15, e0230005	5
878	Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. 2020 , 9,	1
877	Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. 2020 , 15, e0229696	5

876	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. 2020 , 36, 460-466	1
875	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. 2020 , 10, 3925	14
874	The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. 2020 , 12,	6
873	Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement. 2020 ,	7
872	Circulating biomarkers for early detection of hepatocellular carcinoma. 2020 , 13, 1756284820931734	9
871	External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. 2020 , 32, 882-888	4
870	Ramucirumab: A Review in Hepatocellular Carcinoma. 2020 , 80, 315-322	19
869	Low expression of IL-37 protein is correlated with high Oct4 protein expression in hepatocellular carcinoma. 2020 , 737, 144445	3
868	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. 2020 , 72, 990-1002	43
867	Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy. 2019 , 11, 10929-10937	5
866	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. 2020 , 7, 83-92	1
865	Novel Liquid Biopsy Test Based on a Sensitive Methylated Assay for Diagnosing Hepatocellular Carcinoma. 2020 , 4, 461-470	13
864	NAFLD and NASH. 2020 ,	
863	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. 2020 , 72, 2206-2218	49
862	Editorial: the emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. 2020 , 51, 168-169	0
861	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. 2020 , 31, 334-351	64
860	Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression. 2020 , 10, 4	8
859	Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. 2020 , 35, 1277-1287	17

858	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. 2020 , 72, 307-319	133
857	Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. 2020 , 15, e0227424	4
856	Direct Comparison of Four Presurgical Stratifying Schemes for Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced MRI. 2020 , 52, 433-447	5
855	mRECIST for HCC: Performance and novel refinements. 2020 , 72, 288-306	86
854	Milestones in the pathogenesis and management of primary liver cancer. 2020 , 72, 209-214	22
853	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. 2020 , 40, 947-955	10
852	Epidemiology and surveillance for hepatocellular carcinoma: New trends. 2020 , 72, 250-261	263
851	Application of new ultrasound techniques for focal liver lesions. 2020 , 47, 215-237	6
850	Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. 2020 , 55, 222-227	3
849	Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization. 2020 , 15, e0227972	1
848	Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study. 2020 , 20, 43	3
847	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. 2020 , 36, 750-756	1
846	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. 2020 , 16, 975-989	48
845	Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells. 2020 , 11, 2830-2844	6
844	Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study. 2020 , 220, 958-964	9
843	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. 2020 , 35, 1886-1892	4
842	Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. 2020 , 40, 1997-2007	10
841	Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation. 2020 , 11, 414	13

840	Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. 2020 , 10,	9
839	Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. 2020 , 30, 4762-4771	3
838	CEUS LI-RADS: a pictorial review. 2020 , 11, 9	15
837	Changing TACTICS in intermediate HCC: TACE plus sorafenib. 2020 , 69, 1374-1376	4
836	High Squalene Epoxidase in Tumors Predicts Worse Survival in Patients With Hepatocellular Carcinoma: Integrated Bioinformatic Analysis on NAFLD and HCC. 2020 , 27, 1073274820914663	5
835	Comparison of the diagnostic performance of imaging criteria for HCCs ≥ 1.0 cm on gadoxetate disodium-enhanced MRI. <i>Hepatology International</i> , 2020 , 14, 534-543	8.8 7
834	Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma.. 2022 , 9, 116-127	1
833	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. 2020 , 148, 73-81	12
832	Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. 2020 , 20, 99	7
831	The suppressing effects of VEGF-mediated angiogenesis at different administration sequences of apatinib and transarterial embolization .. 2020 , 9, 1133-1143	
830	Sorafenib . Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. 2020 , 40, 2283-2290	18
829	Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. 2020 , 12,	11
828	Treatment of Combined Hepatocellular and Cholangiocarcinoma. 2020 , 12,	17
827	Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. 2021 , 25, 688-697	6
826	Benefits of the 8th American Joint Committee on Cancer System for Hepatocellular Carcinoma Staging. 2021 , 52, 243-248	7
825	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191	63
824	Serum Levels of α -Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. 2021 , 19, 162-170.e4	10
823	Imaging diagnosis of hepatocellular carcinoma: LI-RADS. 2021 , 10, 3	4

822	Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. 2021 , 73, 422-436	68
821	Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. 2021 , 36, 873-884	8
820	A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. 2021 , 26, e367-e373	6
819	Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function?. 2021 , 28, 854-862	5
818	Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. 2021 , 53, 655-675	0
817	Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. 2021 , 45, 101440	
816	Palliative care in hepatocellular carcinoma. 2021 , 36, 618-628	7
815	Is it possible to halve the incidence of liver cancer in China by 2050?. 2021 , 148, 1051-1065	18
814	LI-RADS: Past, Present, and Future, From the Special Series on Radiology Reporting and Data Systems. 2021 , 216, 295-304	4
813	Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI. 2021 , 31, 2321-2331	0
812	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. 2021 , 28, 95-104	4
811	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. 2021 , 51, 406-416	2
810	Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. 2021 , 74, 850-859	6
809	Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?. 2021 , 97, 111-119	1
808	Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. 2021 , 51, 461-471	11
807	Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. 2021 , 31, 3638-3648	7
806	Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. 2021 , 31, 3315-3325	6
805	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. 2021 , 120, 1051-1060	18

804	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. 2021 , 23, 495-505	3
803	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. 2021 , 99, 203-214	7
802	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. 2021 , 18, 223-238	228
801	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. 2021 , 9, 388-397	2
800	5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4 naïve T cells isolated from the peripheral blood of patients with chronic HBV infection. 2021 , 17, 177-185	1
799	EGlutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. 2021 , 32, 419-428.e2	4
798	Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. 2021 , 74, 109-121	15
797	Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. 2021 , 40, 879-894	6
796	Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. 2021 , 13, e1670	16
795	How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?. 2021 , 46, 969-978	3
794	High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. 2021 , 36, 767-774	3
793	Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. 2021 , 28, 20-29	2
792	A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. 2021 , 10,	6
791	A novel internal cold circulation radiofrequency-assisted device for liver transection. 2021 , 38, 308-315	0
790	Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. 2021 , 13,	1
789	Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. 2021 , 21, 284	0
788	In Silico Identification of Contradictory Role of ADAMTS5 in Hepatocellular Carcinoma. 2021 , 20, 1533033820986826	0
787	Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma. 2021 , 18, 364-371	5

- 786 Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. **2021**, 155-168
- 785 Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. **2022**, 31, 35-43 3
- 784 Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. **2021**, 56, 181-190 7
- 783 A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer. **2021**, 9, 337-347 3
- 782 A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. **2021**, 9, 171 6
- 781 Basics of Ablative Radiotherapy: The Background Knowledge Necessary to Practicing Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. **2021**, 93-106
- 780 Current status of image-based surveillance in hepatocellular carcinoma. **2021**, 40, 45-56 3
- 779 Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. **2021**, 13, 659-675 8
- 778 A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic Ga-FAPI-04 PET/CT imaging. **2021**, 8, 8 7
- 777 Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. **2021**, 22, 354-365 10
- 776 Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?. **2021**, 22, 1628-1639 1
- 775 Diagnostic Performance of Simulated Abbreviated MRI for Early-Stage Hepatocellular Carcinoma Screening: A Comparison to Conventional Dynamic Contrast-Enhanced MRI. **2021**, 82, 1218
- 774 Centromere Protein F () Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. **2021**, 12, 2933-2951 4
- 773 Distribution of Hepatitis B Virus Genotypes, Subgenotypes, and Prevalence of Hepatitis B Virus Mutations in Untreated Patients With Chronic Hepatitis B From Mekong Delta. **2021**, 29, e301-e304
- 772 Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. **2021**, 62, 758-766 1
- 771 Application of new ultrasound techniques for focal liver lesions. **2021**,
- 770 Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. **2021**, 259-297
- 769 Hepatocellular Carcinoma in Pakistan: An Update. **2021**, 387-396

768	Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. 2021 , 31, 4492-4503	4
767	A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. 2021 , 18, 3066-3081	5
766	Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma.. 2022 , 11, 13-24	1
765	Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma. 2021 , 12, 2750-2762	1
764	Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. 2021 , 9,	17
763	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. 2021 , 56, 261-273	10
762	Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.. 2022 , 34, 219-225	1
761	Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. 2021 , 21, 70	4
760	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. 2021 , 11, 32-40	3
759	A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. 2021 , 33, 352-363	1
758	Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. 2021 , 31, 4751-4763	3
757	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. 2021 , 27, 64-72	2
756	Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis. 2021 , 7,	
755	Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. 2021 , 2021, 6640121	2
754	MiR-9-5p promotes cell proliferation and migration of hepatocellular carcinoma by targeting CPEB3. 2021 , 15, 97-108	2
753	Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. 2021 , 5, 382-389	1
752	Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. 2021 , 66, 4536-4544	
751	COCH predicts survival and adjuvant TACE response in patients with HCC. 2021 , 21, 275	2

750	Consensus report from the 9 International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. 2021 , 31, 5615-5628		3
749	Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. 2021 , 10, 59-75		9
748	Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. 2021 , 49, 300060521994406		
747	Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. <i>Hepatology International</i> , 2021 , 15, 472-481	8.8	2
746	Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. 2021 , 9, 237		0
745	Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). 2021 , 11, 674-681		1
744	Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. 2021 , 28, 826-836		2
743	Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. 2021 , 12, e00310		2
742	Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. 2021 , 148, 2924-2934		1
741	Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma. 2021 , 13,		1
740	Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. 2021 , 11, 1882		1
739	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. 2021 , 10,		2
738	A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. 2021 , 11, 569515		
737	Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. 2021 , 11,		4
736	Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. 2021 , 11, 6814		0
735	Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. 2021 , 5, 10		1
734	Nomogram for Predicting the Prognosis of Patients with Hepatocellular Carcinoma Presenting with Pulmonary Metastasis. 2021 , 13, 2083-2094		1
733	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. 2021 , 10,		2

732	Artificial intelligence in precision medicine in hepatology. 2021 , 36, 569-580	12
731	Diagnostic performance of MRI using extracellular contrast agents versus gadoteric acid for hepatocellular carcinoma: A systematic review and meta-analysis. 2021 , 41, 1117-1128	6
730	Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. 2021 , 146, 48-55	2
729	Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. 2021 , 21, 409	2
728	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. 2021 , 41, 1265-1277	7
727	Comparing the Safety and Efficacy of Microwave Ablation Using Thermosphere Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. 2021 , 13,	1
726	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. 2021 , 25, 1078-1079	1
725	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. 2021 , 13,	3
724	Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. 2021 , 21, 250	2
723	Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model. 2021 , 16, e0248352	2
722	Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. 2021 , 11,	3
721	Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study. 2021 , 11, 570312	1
720	Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?. 2021 , 12, 31	7
719	Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. 2021 , 9, 301-314	1
718	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. 2021 , 44, 1048-1059	6
717	Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. 2021 , 11,	0
716	Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study. 2021 , 19, 95	5
715	Moscatin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF- κ -Dependent Pathway. 2021 , 22,	1

714	Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. 2021 , 21, 283	0
713	Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. 2021 , 16, 550-554	1
712	Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. 2021 , 77, 115-122	1
711	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. 2021 , 156, 120-126	9
710	The review of international clinical guidelines and clinical trial results for the diagnosis of hepatocellular cancer (HCC) for the period 2014-2020. 2021 , 26, 12-24	1
709	Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. 2021 , 11, 6041	0
708	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. 2021 , 46, 3708-3716	1
707	External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. 2021 , 21, 25-33	1
706	How to Treat Hepatocellular Carcinoma in Elderly Patients. 2021 , 14,	1
705	Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. 2021 ,	1
704	Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool?. 2021 ,	7
703	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. 2021 , 10,	5
702	Using contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma - what we have and have not achieved. 2021 , 42, 120-124	
701	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. 2021 , 46, 3528-3539	2
700	Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B. 2021 , 28, 1034-1041	2
699	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. 2021 , 549, 171-178	3
698	Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. 2021 , 9, 624	1
697	PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. 2021 , 21, 401	13

696	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. 2021 , 116, 1698-1708	2
695	Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS /ESCALAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study. 2021 , 31, 7614-7625	6
694	C8B in Complement and Coagulation Cascades Signaling Pathway is a predictor for Survival in HBV-Related Hepatocellular Carcinoma Patients. 2021 , 13, 3503-3515	2
693	Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. 2021 , 31, 8649-8661	2
692	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. 2021 , 4, CD013346	11
691	Advances in immunotherapy for hepatocellular carcinoma. 2021 , 18, 525-543	113
690	Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. 2021 , 31, 7760-7770	0
689	Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. 2021 , 14, 119	0
688	α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. 2021 , 124, 1988-1996	3
687	Hepatobiliary contrast agents in MR: Where we stand and future perspectives. 2021 , 41, 888-890	
686	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. 2021 , 22, 1217-1224	1
685	NAFLD-Associated HCC: Progress and Opportunities. 2021 , 8, 223-239	11
684	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. 2021 , 11, 8184	3
683	Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). 2021 , 40, 237-247	0
682	Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. <i>Hepatology International</i> , 2021 , 15, 642-650	8.8 6
681	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. 2021 , 41, 1922-1932	5
680	Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoteric acid-enhanced magnetic resonance imaging. 2021 , 31, 7696-7704	4
679	Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma?. 2021 , 10,	0

678	Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. 2021 , 41,		1
677	Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. 2021 , 1, 48-66		
676	Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies. 2021 , 9, 273-295		
675	Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. 2021 , 11, 299-304		0
674	Prognosis prediction or treatment allocation?. <i>Hepatology International</i> , 2021 , 15, 852-854	8.8	
673	A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. 2021 , 24, 733-743		1
672	Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. 2021 , 120, 1259-1268		2
671	Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. 2021 , 13,		5
670	To explore the curative effect of CT-guided Iodine-125 radioactive seed implantation in the treatment of stage IV primary hepatocellular carcinoma. 2021 , 4, 82-86		
669	Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. 2021 , 1, 29-47		2
668	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. <i>Hepatology International</i> , 2021 , 15, 946-956	8.8	2
667	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. 2021 , 13,		0
666	Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. 2021 , 24, 82-89		1
665	Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3 cm. <i>Hepatology International</i> , 2021 , 15, 676-684	8.8	0
664	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. 2021 , 46, 3625-3633		1
663	Preoperative Gadoteric Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy. 2021 , 11, 649682		2
662	Chronic alcohol exposure promotes HCC stemness and metastasis through -catenin/miR-22-3p/TET2 axis. 2021 , 13, 14433-14455		4
661	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. 2021 , 13,		9

660	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. 2021 , 27, 2434-2457	5
659	Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. 2021 , 31, 9306-9315	0
658	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. 2021 , 16, e0249426	5
657	US LI-RADS Visualization Score: Interobserver Variability and Association With Cause of Liver Disease, Sex, and Body Mass Index. 2021 , 8465371211012104	0
656	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.	2
655	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. 2021 , 51, 880-889	4
654	Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. 2021 , 120, 1249-1258	3
653	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. 2021 , 10, 181-223	38
652	Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. 2021 , 13, 4013-4029	2
651	CaCO ₃ -Encapsulated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma. 2021 , 10, e2100748	4
650	Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. 2021 ,	0
649	Non-contrast Magnetic Resonance Imaging versus the Multiphase Computed Tomography with Respect to the Asia-Pacific Clinical Practice Guidelines: A Diagnostic Performance Study for Liver Cancer. 2021 , 32, 318-326	1
648	Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. 2021 , 15, 155-160	3
647	Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. 2021 , 8, 657-670	3
646	A Multi-Scale and Multi-Level Fusion Approach for Deep Learning-Based Liver Lesion Diagnosis in Magnetic Resonance Images with Visual Explanation. 2021 , 11,	0
645	Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. 2021 ,	1
644	LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. 2022 , 32, 46-55	1
643	Regulatory Role of SFN Gene in Hepatocellular Carcinoma and Its Mechanism. 2021 , 26, 375-383	0

642	Irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis. 2021 , 25, 340-349	3
641	Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. 2021 , 8, 625-644	3
640	Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. 2020 , 8, HEP32	2
639	Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. 2021 , 4, e2114680	4
638	Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma. 2021 , 11, 2521-2540	3
637	VIRUS-ASSOCIATED HEPATOCELLULAR LIVER CANCER. 2021 , 5, 17-24	1
636	Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. 2021 , 10, 100090	8
635	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. 2021 , 8, 613-623	2
634	Comparison of Conventional Gadoxetate Disodium-Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion. 2021 , 216, 1510-1520	7
633	Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?. 2021 , 27, 2784-2794	4
632	Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana. 2021 , 16, e0253759	1
631	Donafenib treatment for hepatocellular carcinoma: A case report. 2021 , 100, e26373	1
630	A Case of Refractory Esophageal Ulcer Caused by Radiotherapy for Hepatocellular Carcinoma. 2021 , 12, 67-72	
629	Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. 2021 , 13,	1
628	Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. 2021 , 16, e0252678	0
627	Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma. 2021 , 23, 420-431	0
626	Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. 2021 , 51, 957-967	6
625	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. 2021 , 27, 4104-4142	1

624	Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. 2021 , 2021, 6670367	3
623	Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. 2021 , 13,	0
622	HMGCS2 in metabolic pathways was associated with overall survival in hepatocellular carcinoma: A LASSO-derived study. 2021 , 104, 368504211031749	0
621	A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. 2021 , 5, 1015-1018	1
620	Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria.. 2021 , 10, 629-640	9
619	Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. 2021 , 8, 145-152	1
618	Bisegmentectomy 7-8 for Small-for-Size Remanant Liver for Cirrhotic Patients Under Right Hemi-hepatectomy With Hepatocellular Carcinoma: A Case-Matched Comparative Study. 2021 , 8, 675666	1
617	Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. 2021 , 9, 1130	0
616	CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. 2021 , 9, 1076	4
615	Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. 2021 ,	0
614	Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center. 2021 ,	
613	Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. 2021 , 13,	
612	The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. 2021 , 100, e26414	
611	External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. 2021 , 28, 1373-1380	1
610	Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. 2021 , 41, 2768-2776	2
609	Scutellaria barbata D.Don and Oldenlandia diffusa (Willd.) Roxb crude extracts inhibit hepatitis-B-virus-associated hepatocellular carcinoma growth through regulating circRNA expression. 2021 , 275, 114110	2
608	Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. 2021 , 28, 1431-1442	1
607	HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3. 2021 , 74, 1480-1495	9

606	Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. 2021 , 1	0
605	Circ_0027089 regulates NACC1 by targeting miR-136-5p to aggravate the development of hepatitis B virus-related hepatocellular carcinoma. 2021 , 33,	2
604	Validation and update of a multivariable prediction model for the identification and management of patients at risk for hepatocellular carcinoma. 2021 , 18, 21	1
603	Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. 2021 , 13, 949-968	0
602	Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma. 2021 , 11, 700711	0
601	Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. 2021 , 65, 956-968	3
600	Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via μ -opioid receptor. 2021 ,	0
599	HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?. 2021 , 3, 100320	0
598	MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. 2021 , 29, 329-345	0
597	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.. 2022 , 10, 147-158	4
596	Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. 2021 , 1	4
595	Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. 2021 , 11, 733595	2
594	Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. 2021 , 29, 279-290	
593	Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (. 2021 , 8, 937-949	3
592	Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis. 2021 , 276, 114174	3
591	Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. 2021 , 130, 374-384	2
590	Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. 2021 , 22, 566	5
589	Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. 2021 , 32, 1194-1202	2

588	Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. 2021 , 16, e0255605		1
587	Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia. 2021 , 1		0
586	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. 2021 ,		3
585	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021 , 15, 1083-1092	8.8	5
584	Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumorcidal CD8 T-Cell Infiltration in Rabbit VX2 Liver Tumor. 2021 , 13, 6943-6952		1
583	Progress of MRI Radiomics in Hepatocellular Carcinoma. 2021 , 11, 698373		0
582	Clinical Study on Effect of Solution Focused Approach on the Complications, Pain, Sleep, and Quality of Life in Patients with Hepatocellular Carcinoma Undergoing TACE. 2021 , 2021, 5068228		0
581	Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2021 , 11,		2
580	Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. 2021 , 19, 418-427		1
579	Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. 2021 , 11,		2
578	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. 2021 , 32, 1267-1276.e1		6
577	Diagnostic Accuracy of Serum/Plasma Circular RNAs and the Combination of Circular RNAs and α -Fetoprotein for Detecting Hepatocellular Carcinoma: A Meta-Analysis. 2021 , 12, 722208		2
576	Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial. 2021 , 21, 146-154		0
575	Long Noncoding RNA Context-Dependently Regulates by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. 2021 , 11, 592045		1
574	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. 2021 , 5, 1972-1986		4
573	Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. 2021 , 11, 709278		1
572	The lncRNA Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis. 2021 , 40, 1278-1289		1
571	A New Clinical Nomogram From the TCGA Database to Predict the Prognosis of Hepatocellular Carcinoma. 2021 , 11, 698980		0

570	Changing clinical management of NAFLD in Asia. 2021,	2
569	Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. 2021, 217, 644-650	0
568	P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. 2021, 25, 9168-9182	3
567	Hepatocellular Carcinoma: Diagnosis and Surveillance.	0
566	Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. 2021, 11, 686962	2
565	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. 2021,	2
564	LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?. 2021, 1	
563	Paradigm shift in the treatment options of hepatocellular carcinoma. 2021,	3
562	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. 2021 , 27, 5536-5554	3
561	Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. 2021, 142, 109890	1
560	Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. 2021, 13,	2
559	Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study. 2021, 46, 5735-5745	0
558	Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma. 2021, 22, 48	1
557	Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. 2021, 101799	2
556	Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. 2021, 22,	1
555	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. 2021, 11, 635731	2
554	Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver?. 2021, 47, 2930-2935	1
553	Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: A multicenter study. 2021, 143, 109891	3

- 552 Surveillance for hepatocellular carcinoma at the community level: Easier said than done. **2021**, 27, 6180-6190 0
- 551 The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. **2021**, 14, 6343-6358 1
- 550 Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. **2021**, 25, 785-803 2
- 549 A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. **2021**, 14, 101200 1
- 548 Focal hepatic intrinsically hyperattenuating lesions at unenhanced CT: Not always calcifications. **2021**, 80, 304-314
- 547 Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. **2021**, 281, 114539 4
- 546 The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma. **2021**, 46, 2527-2539
- 545 Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. **2021**, 4
- 544 Overview of Clinical HCC and Its Management. **2021**, 111-126
- 543 Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. **2021**, 9, 55 1
- 542 Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. **2021**, 10, 137-150 2
- 541 Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. **2021**, 19, 329-337 3
- 540 Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma. **2021**, 12, 6231-6241
- 539 A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma.. **2021**, 10, 3979-3992 0
- 538 Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. **2021**, 277-283
- 537 Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. **2021**, 16, e0244939 3
- 536 Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma. **2021**, 12, 2361-2376
- 535 Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. **2021**, 18, 293-313 80

534	Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. 2021 , 21, 11		5
533	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. 2021 , 10, 38-51		17
532	Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. 2021 , 33, 380-387		
531	Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. 2021 , 10, 522-534		1
530	Laboratory Tests in Liver Diseases. 2019 , 19-34		1
529	HBV Genome and Life Cycle. 2020 , 1179, 17-37		8
528	Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. <i>Hepatology International</i> , 2020 , 14, 415-428	8.8	42
527	A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. <i>Hepatology International</i> , 2020 , 14, 1034-1047	8.8	13
526	Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?. 2020 , 62, 63-68		12
525	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. 2020 , 5, 1039-1052		27
524	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. 2021 , 33, 885-893		3
523	Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. 2020 , 111, 1500-1513		7
522	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). 2020 , 9, 682-720		108
521	Perfluorobutane contrast-enhanced ultrasonography: a new standard for ultrasonography-guided thermal ablation of sonographically occult liver tumours?. 2020 ,		2
520	MicroRNA-32 Regulates Development and Progression of Hepatocellular Carcinoma by Targeting ADAMTS9 and Affects Its Prognosis. 2018 , 24, 177-187		5
519	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. 2020 , 15, e0233212		9
518	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. 2020 , 15, e0239733		3
517	Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. 2019 , 7, 72-85		18

516	Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. 2019 , 7, 183-190	23
515	Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. 2021 , 116, 57-67	7
514	Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. 2021 , 116, 411-415	2
513	Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?. 2019 , 38, 200-214	25
512	Comparison of MicroFlow Imaging with color and power Doppler imaging for detecting and characterizing blood flow signals in hepatocellular carcinoma. 2020 , 39, 85-93	10
511	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. 2019 , 19, 108-116	4
510	Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. 2020 , 20, 25-31	3
509	Hepatocellular Carcinoma in Oman: An analysis of 284 cases. 2020 , 20, e316-e322	3
508	APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. 2020 , 12, 4573-4591	21
507	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. 2020 , 6,	7
506	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. 2020 , 6,	6
505	Non-invasive biomarkers for the detection of hepatocellular carcinoma. 2019 , 31,	13
504	The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. 2020 , 76, 155-160	5
503	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96
502	Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging?. 2020 , 21, 280-289	5
501	Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. 2019 , 25, 245-263	104
500	Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. 2019 , 25, 223-233	21
499	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. 2019 , 25, 335-343	23

498	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
497	Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?. 2019 , 25, 264-269	31
496	Application of artificial intelligence in hepatology: Minireview. 2020 , 1, 5-11	5
495	What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?. 2020 , 2, 265-268	2
494	Pediatric hepatocellular carcinoma. 2018 , 24, 3980-3999	53
493	Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. 2018 , 24, 4224-4229	12
492	Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. 2018 , 24, 5215-5222	14
491	Hepatocellular carcinoma surveillance: An evidence-based approach. 2019 , 25, 1550-1559	62
490	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. 2019 , 25, 3704-3721	54
489	Role of liver biopsy in hepatocellular carcinoma. 2019 , 25, 6041-6052	33
488	Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. 2020 , 26, 393-403	16
487	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. 2020 , 14, 515	1
486	Deep learning with convolutional neural networks for identification of liver masses and hepatocellular carcinoma: A systematic review. 2019 , 11, 1218-1230	36
485	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. 2020 , 12, 663-676	5
484	High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. 2018 , 10, 116-123	6
483	MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. 2018 , 10, 462-473	14
482	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. 2018 , 10, 485-495	19
481	Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy. 2018 , 10, 571-584	14

480	The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. 2020 , 14, 108-116	6
479	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 13, 227-299	151
478	Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. 2020 , 8, e10382	4
477	Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System. 2019 , 11, e5774	15
476	Diagnosis and Evaluation of Hepatocellular Carcinoma. 2021 , 1-22	
475	Histogram peritumoral enhanced features on MRI arterial phase with extracellular contrast agent can improve prediction of microvascular invasion of hepatocellular carcinoma.. 2022 , 12, 1372-1384	0
474	Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study.. 2022 , 9, nwab192	0
473	LI-RADS version 2018 in Patients with Prior History of Hepatocellular Carcinoma: Are LR4 Observations Enough for the Diagnosis of Recurrent HCC?. 2021 , 25, 172	1
472	Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. 2021 , 1	4
471	Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis. 2021 , 1	1
470	High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma. 2021 , 2021, 5680968	0
469	Current epidemiology in hepatocellular carcinoma. 2021 , 15, 1295-1307	15
468	Care After Cure: Long-term Follow-up in Hepatitis C. 1	
467	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. 2021 , JCO2100608	15
466	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. 2021 ,	1
465	Operative Microwave Ablation for Hepatocellular Carcinoma Within 3 cm and 3 Nodules: Experience in 559 Patients. 2021 , 1	1
464	Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. 2021 , 8, 1233-1240	3
463	Aberrant STAT1 methylation as a non-invasive biomarker in blood of HCV induced hepatocellular carcinoma. 2021 ,	0

462	Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. 2021 , 13, 1245-1257	1
461	Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. 2021 , 10, CD013362	5
460	Minimally Invasive Surgery for Hepatocellular Carcinoma; Latest Advances.	
459	Blood Flow Diversion Within Hepatocellular Carcinoma (HCC) after Selective Occlusion of Feeding Arteries (SOFA) and Feasibility of Utilizing the SOFA Technique in Transarterial Chemoembolization (SOFA-TACE). 2021 , 1	0
458	Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma. 2021 , 13, 7973-7980	1
457	Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. 2021 , 35, 2211-2213	
456	Invasive methods of hepatocellular carcinoma treatment. 2017 , 4, 11-13	
455	Hepatocellular Carcinoma: Known and Emerging Risk Factors. 2018 , 09, 417-437	
454	Maligne Lebertumoren. 2018 , 107-131	
453	Preoperative Preparations for Patients with Hepatocellular Carcinoma. 2019 , 7-26	
452	Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature. 2018 , 10, 772-779	
451	Outcome and predictors of transarterial chemo embolization in decompensate cirrhotic hepatocellular carcinoma patients. 2018 , 9,	
450	Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. 2019 , 195-224	1
449	Ablation for Liver Tumors. 2019 , 65, 433-443	
448	Bridging Therapy for HCC. 2019 , 191-203	
447	Analysis of Existing Guidelines and Randomized, Controlled, Clinical Trials for Development of [Guideline of Clinical Trial on Herbal Medicinal Product for Liver Cancer]. 2019 , 40, 89-116	
446	Liver Transplantation after Successful Downstaging with Hepatic Arterial Infusion Chemotherapy in a Patient with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. 2019 , 19, 64-68	
445	Surgical management of hepatocellular carcinoma-Western versus Eastern attitude.. 2019 , 8, S245-S260	

- 444 Hepatocellular carcinoma successfully treated with ALPPS and apatinib: A case report. **2019**, 7, 2384-2392
- 443 Contrast-enhanced Ultrasonography: The Third Modality for Differentiation of Liver Mass. **2019**, 19, 91-96
- 442 Potential prognostic factors for solitary hepatocellular carcinoma \geq 5 cm after transarterial chemoembolization. **2019**, 34, 1210-1211
- 441 Hepatocellular Carcinoma in Budd-Chiari Syndrome. **2020**, 113-129
- 440 Assessment of the follow-up interval changes of the less than 2 cm arterial phase enhancing hepatic nodules in correlation with Liver Imaging Reporting and Data System (LI-RADS) classification version 18 using contrast-enhanced multidetector computed tomography. **2019**, 50, 1
- 439 Hepatic resection versus TILA-TACE in the treatment of Resectable Hepatocellular Carcinoma: study protocol for a randomized controlled trial.
- 438 Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. **2020**, 11, 115-123
- 437 Roles of Tumor Markers in Diagnosis and Treatment of Hepatocellular Carcinoma. **2020**, 95, 31-35
- 436 Cryoablation combined with radiotherapy for hepatic malignancy: Five case reports. **2020**, 12, 237-247 3
- 435 Combined extensive liver resections in patients with locally advanced hepatocellular cancer \square clinical cases. **2020**, 7, 154-163
- 434 Screening for hepatocellular carcinoma in chronic liver disease: a systematic review and meta-analysis of randomized controlled trials comparing screening methodologies.
- 433 The Long-Term Efficacy of Radiofrequency Ablation Versus Laparoscopic Hepatectomy for Small Hepatocellular Carcinoma in East Asia: A Systematic Review and Meta-Analysis. **2020**, 22,
- 432 Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. **2021**, 100, e27470
- 431 Evaluating the liver function of patients with hepatocellular carcinoma. **2021**, 51, 1095-1096 0
- 430 Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. **2021**, 11, 719973 0
- 429 Optimal Modalities for HCC Surveillance in a High-Incidence Region. **2020**, 16, 236-239
- 428 Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. **2020**, 13, 194 1
- 427 Propofol midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. **2021**, 5, 273-279 1

426 Medicina basada en la evidencia y la lectura crítica en hepatología. **2020**, 68-76

425 Application of Convolutional Neural Networks in Gastrointestinal and Liver Cancer Images: A Systematic Review. **2020**, 183-211

424 Investigation of the Utility and Safety of Dynamic Computed Tomography with Vasodilators. **2020**, 63, 47-54 1

423 Diagnostic Value of the Hypomethylation of the WISP1 Promoter in Patients with Hepatocellular Carcinoma Associated with Hepatitis B Virus. **2020**, 252, 297-307

422 NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers. **2020**, 199-209

421 Liver Cancer. **2020**, 341-368

420 HCC in Patients with NAFLD/NASH. **2020**, 191-203

419 Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. **2021**, 2021, 4973589 1

418 Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. **2021**, 55, 350 2

417 Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. **2021**, 31348211054532 1

416 Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. **2021**, 21, 418 2

415 Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. **2020**, 26, 3975-3988 1

414 Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. **2020**, 26, 3971-3984

413 Percutaneous Ablation of Liver Tumors. **2021**, 269-282

412 Transarterial Chemoembolisation and Combined Therapy. **2021**, 283-317

411 Hepatocellular Carcinoma: Diagnostic Guidelines. **2021**, 191-213

410 Determinants of pain in advanced HCC patients receiving hepatic artery infusion chemotherapy. **2021**, 39, 394-399 1

409 Disparities in Liver Cancer Surveillance Among People With Disabilities: A National Database Study in Korea. **2021**, 55, 439-448 1

408	Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis.	
407	Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. 2018 , 19, 2043-2055	2
406	[Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study]. 2019 , 39, 633-640	1
405	Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. 2018 , 11, 2092-2099	4
404	Low MYH9 expression predicts a good prognosis for hepatocellular carcinoma. 2018 , 11, 2784-2791	2
403	Elevated GSK3 β expression predicts good prognosis in hepatocellular carcinoma. 2018 , 11, 2776-2783	
402	Recent progress in treatment of hepatocellular carcinoma. 2020 , 10, 2993-3036	48
401	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. 2020 , 13, 1337-1342	
400	Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. 2020 , 16, 506-516	3
399	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. 2021 ,	1
398	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. 2021 ,	1
397	The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. 2021 , 2021, 7377299	0
396	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. 2021 , 13,	5
395	Changes in therapeutic options for hepatocellular carcinoma in Asia. 2021 ,	1
394	[Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis]. 2021 , 78, 255-260	0
393	A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS. 2021 , 1	0
392	'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. 2021 ,	0
391	Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities.. 2021 , 13, 1568-1583	2

390	Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.. 2021 , 11, 726213	4
389	Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma. 2021 ,	4
388	Guidewire-catheter induced hydrodissection to assist radiofrequency ablation for subcapsular hepatocellular carcinoma with iodized oil retention in patients with failed artificial ascites due to perihepatic adhesion. 2021 , 27, 746-753	
387	Correlation of clinico-pathological profile, prognostic factors, and survival outcomes with baseline alfa-fetoprotein levels in patients with hepatocellular carcinoma: a biomarker that is bruised but not broken. 2021 ,	
386	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. 2021 ,	6
385	Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. 2021 , 11, 740762	1
384	Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoteric Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma. 2021 , 102, 284-295	
383	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. 2021 , 13,	1
382	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. 2021 ,	2
381	Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma. 2021 , 14, 9145-9152	
380	Orosomuroid in liver diseases.. 2021 , 27, 7739-7747	1
379	Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.. 2021 ,	0
378	Surgical Management of Hepatocellular Carcinoma. 2021 , 1-16	
377	Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.. 2022 , 11, 78-93	1
376	Viral hepatitis in 2021: The challenges remaining and how we should tackle them.. 2022 , 28, 76-95	1
375	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice.. 2022 ,	2
374	Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomic features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study.. 2022 ,	0
373	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.. 2022 , 14,	3

372	Hepatobiliary-Phase Hypointense Nodules without Arterial Phase Hyperenhancement: Time to Act.. 2021 ,		
371	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. 2021 , 13, 1337-1342		0
370	A preliminary study of the clinical significance of folate receptor-positive circulating tumor cell in the management of hepatobiliary-pancreatic cancers.. 2020 , 9, 6700-6709		
369	Robust End-to-End Focal Liver Lesion Detection Using Unregistered Multiphase Computed Tomography Images. 2021 , 1-11		0
368	Diagnostic Image Feature and Performance of CT and Gadoteric Acid Disodium-Enhanced MRI in Distinction of Combined Hepatocellular-Cholangiocarcinoma from Hepatocellular Carcinoma. 2021 , 25, 313		
367	Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience.. 2022 , 14,		3
366	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.. 2022 , 57, 90		0
365	Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma.. 2022 , 14, 249-255		1
364	Medical Treatment for Hepatocellular Carcinoma in Japan.. 2022 ,		1
363	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.. 2022 , 28, 310-331		4
362	Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.. 2021 , 9, 784718		0
361	Development of Novel Deep Multimodal Representation Learning-based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images.. 2021 ,		0
360	Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study.. <i>Hepatology International</i> , 2022 , 16, 159	8.8	2
359	Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging.. 2022 ,		1
358	Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.. 2022 , 101, e28545		1
357	Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.. 2022 , 29, 565-577		
356	Treatment and the prognosis of hepatocellular carcinoma in Asia. 2021 ,		3
355	Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.. 2022 , 28, 216-229		3

354	GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.. <i>Hepatology International</i> , 2022 , 16, 148	8.8	0
353	Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma.. 2022 ,		1
352	Deep Learning Model With Convolutional Neural Network for Detecting and Segmenting Hepatocellular Carcinoma in CT: A Preliminary Study.. 2022 , 14, e21347		0
351	Urine DNA biomarkers for hepatocellular carcinoma screening.. 2022 ,		2
350	Development of a prognostic gene signature for hepatocellular carcinoma.. 2022 , 31, 100511		0
349	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.. 2022 , 23, 77-90		58
348	Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.. 2022 , 17, e0262267		0
347	BCLC 2022 update: Important advances, but missing external beam radiotherapy.. 2022 ,		3
346	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. 2022 , 60, e56-e130		0
345	Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria" .. <i>Hepatology International</i> , 2022 , 16, 209	8.8	
344	Iodized oil CT-guided radiofrequency ablation for hepatocellular carcinoma within Milan criteria.. <i>Hepatology International</i> , 2022 , 16, 207	8.8	
343	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.. 2022 , 12,		3
342	In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma.. 2022 , 17, 11		1
341	Establishing an Ultrasound Screening Protocol for Chronic Liver Disease with a Handheld Device: A Pilot Project in Southern Ethiopia.. 2022 ,		1
340	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.. 2022 ,		
339	Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.. 2022 ,		0
338	Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization.. 2022 , 12,		0
337	Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019.. 2022 ,		0

- 336 Models to Predict Development or Recurrence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis.. **2022**, 24, 1 0
- 335 Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.. **2022**, 28, 665-674 0
- 334 Role of perfusion features in contrast-enhanced ultrasound differential diagnosis of hepatocellular adenoma and carcinoma: Far beyond the gray-scale ultrasound.. **2022**, 50, 222-223
- 333 Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.. **2021**, 8, 810251 1
- 332 The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation.. **2021**, 1
- 331 HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. **2021**, 7
- 330 VueBox[®] for quantitative analysis of contrast-enhanced ultrasound in liver tumors.. **2021**, 1
- 329 Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma.. **2022**, 11, 669-677 0
- 328 HAMP Is a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma.
- 327 Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization.. **2022**, 13, 1914-1922
- 326 A new method for early diagnosis of liver cancer using a biosensor embedded in an alginate polymer thin film.
- 325 Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells.. **2022**, 14, 0
- 324 LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA.. **2022**, 36, e22238 2
- 323 Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review.. **2022**, 0
- 322 Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.. **2022**, 3
- 321 The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.. **2022**, 16, 3
- 320 Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.. **2022**, 17, e0263298 1
- 319 The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients.. **2022**, 2022, 1817694

318	Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoteric acid-enhanced 3.0 T MRI.. 2022 , 12, e058461		
317	New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients.. 2022 , 12, 812832		0
316	Cross-cultural adaptation and validation of a Chinese Preventive Health Model instrument for measuring the psychosocial factors in hepatocellular carcinoma screening among patients with hepatitis B.. 2022 ,		
315	Drug delivery strategy in hepatocellular carcinoma therapy.. 2022 , 20, 26		1
314	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma.. <i>Hepatology International</i> , 2022 , 1	8.8	0
313	Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: a real-world data from Electronic Health Record. 2022 ,		
312	Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation.. 2022 , 2022, 3569644		
311	Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.. 2022 , 1		0
310	Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma.. 2022 , 9, 189-201		1
309	Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II).. 2022 , 113, 106-108		
308	Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies.. 2022 ,		1
307	II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico. 2022 ,		
306	TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis.. 2022 , 1-9		0
305	Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study.. <i>Hepatology International</i> , 2022 , 1	8.8	1
304	New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study.. 2022 , 12, 796311		
303	LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions.. 2022 , 1		
302	Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma.. 2022 , 1		0
301	An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma.. 2022 , 13, 854851		0

300	Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement.. 2022 ,	0
299	Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.. 2022 , 23, 89-95	0
298	A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma.. 2022 , 12, 745258	1
297	Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.. 2022 ,	1
296	A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.. 2022 ,	3
295	Reliability of extracellular contrast vs. gadoxetic acid in assessing small liver lesions using LI-RADS v.2018 and EASL criteria.. 2022 ,	0
294	Liver Surgery: Important Considerations for Pre- and Postoperative Imaging.. 2022 , 210124	0
293	High-throughput site-specific N-glycoproteomics reveals glyco-signatures for liver disease diagnosis.	0
292	Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma.. 2022 , 38, 102811	1
291	Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan.. 2022 , 30, 76-82	
290	Diagnostic accuracy of three-dimensional contrast-enhanced ultrasound for focal liver lesions: A protocol for systematic review and meta-analysis.. 2021 , 100, e28147	
289	Imaging Diagnosis of HCC: Future directions with special emphasis on hepatobiliary MRI and contrast-enhanced ultrasound.. 2021 ,	1
288	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.. 2022 , 11, 48-60	1
287	Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis.. 2021 , 13,	1
286	Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.. 2021 , 11, 680691	1
285	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.. 2021 , 13, 1919-1938	0
284	Liver resection radiofrequency ablation in single hepatocellular carcinoma of posterosuperior segments in elderly patients.. 2021 , 13, 1696-1707	1
283	Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.. 2021 , 13,	0

282 Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea.. **2021**, 1

281 Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.. **2021**, 5

280 Diagnostic Accuracy of Circular RNAs in Different Types of Samples for Detecting Hepatocellular Carcinoma: A Meta-Analysis.. **2021**, 12, 794105

279 Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.. **2021**, 8, 1565-1577 1

278 Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma.. **2022**, 14, 0

277 Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.. **2022**, 1

276 The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis.. **2022**,

275 Editorial: screening for hepatocellular carcinoma in NAFLD-towards abbreviated MRI alternative in patients with obesity?. **2022**, 55, 1210-1211 0

274 Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas.. **2022**, 1 1

273 Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses.. **2022**,

272 Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information.. **2022**, 1

271 Data_Sheet_1.pdf. **2020**,

270 Table_1.docx. **2020**,

269 Data_Sheet_1.pdf. **2020**,

268 Data_Sheet_2.pdf. **2020**,

267 Data_Sheet_3.pdf. **2020**,

266 DataSheet_1.pdf. **2020**,

265 Table_1.xlsx. **2020**,

264 Table_2.xlsx. **2020**,

263 Table_3.xlsx. **2020**,

262 Table_4.xlsx. **2020**,

261 Table_5.xlsx. **2020**,

260 Image_1.tif. **2019**,

259 Image_2.tif. **2019**,

258 Table_1.docx. **2019**,

257 Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory.. **2022**, 12, 839605 0

256 Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.. **2021**, 7, 811-833

255 Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence.. **2022**, 8, 71-79

254 Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.. **2022**, 1

253 Application and progress of the detection technologies in hepatocellular carcinoma. **2022**, 2

252 Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies.. **2022**, 0

251 Hepatitis B Virus-Associated Hepatocellular Carcinoma. **2022**, 14, 986 4

250 Start of an era: circulating cell-free DNA for early detection of cancers. **2022**, 100259 0

249 Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.. **2022**, 5, CD014798 1

248 Establishment and Analysis of a Combined Diagnostic Model of Liver Cancer with Random Forest and Artificial Neural Network. **2022**, 2022, 1-17

247 Usefulness of Imaging and Biological Tools for the Characterization of Portal Vein Thrombosis in Hepatocellular Carcinoma. **2022**, 12, 1145

246	Free-breathing dynamic T1WI using compressed sensing-golden angle radial sparse parallel imaging for liver MRI in patients with limited breath-holding capability. 2022 , 110342	1
245	MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.. 2022 , 1	0
244	Short- and long-term outcomes after robotic and open liver resection for elderly patients with hepatocellular carcinoma: a propensity score-matched study.. 2022 ,	0
243	Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. 2022 , 10, 3989-4019	0
242	The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. 2022 , 3, e163	0
241	Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.. 2022 ,	0
240	Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.	3
239	The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial.. 2022 ,	
238	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. 2022 , 3, 386-401	8
237	Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.. 2022 ,	0
236	The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications.. 2022 , 106261	1
235	Fibrosis-stage Specific Incidence of Hepatocellular Cancer after Hepatitis C Cure with Direct-Acting Antivirals: A Systematic Review & Meta-analysis.. 2022 ,	1
234	Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high-risk chronic hepatitis B patients for HCC surveillance in Thailand.	
233	Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. 2022 , 28, 2176-2183	2
232	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. 2022 , 14, 2549	0
231	A Prospective Study for Validation of General Evaluation Score for Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis C Patients.	
230	Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. 12,	0
229	Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. 2022 , 11, 3093	

- 228 Low utilization of external beam radiation therapy for patients with unresectable hepatocellular carcinoma: An analysis of the United Network for Organ Sharing database. **2022,**
- 227 A Novel Prognostic Score Based on Artificial Intelligence in Hepatocellular Carcinoma: A Long-Term Follow-Up Analysis. **2022, 12,** ○
- 226 Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. **12,**
- 225 Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. **2022, 102, 106094** ○
- 224 Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Volume 9, 517-536
- 223 Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. **1**
- 222 An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B/C in patients with huge hepatocellular carcinoma: a multi-institutional study. **2022, 20,** ○
- 221 Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound. **2**
- 220 MRI in liver cirrhosis.
- 219 lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound. **2022, 20,**
- 218 Multi-Sequence MR-Based Radiomics Signature for Predicting Early Recurrence in Solitary Hepatocellular Carcinoma ≤ 5 cm. **12,** ○
- 217 Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
- 216 OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells.
- 215 Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. ○
- 214 Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. **9,**
- 213 PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. ○
- 212 The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma. **2022, 2022, 1-9**
- 211 Moving Away from a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. **2022,** Publish Ahead of Print,

- 210 Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three $\leq 3\text{-cm}$ nodules in a single institute.
- 209 Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population. **2022**, 22,
- 208 Inhibitory effect of lingonberry extract on HepG2 cell proliferation, apoptosis, migration, and invasion. **2022**, 17, e0270677 0
- 207 TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. 0
- 206 Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. 1-8
- 205 Interventional oncology of liver tumors: how it all started and where are we now. 1
- 204 Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). 0
- 203 Safety and efficacy of pentazocine–hidazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma.
- 202 The role of nursing in the hepatic rehabilitation of patients with liver cirrhosis. **2022**, 20, S18-S25
- 201 Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. **2022**, 0
- 200 Combined Liver Stiffness and α -fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C. **2022**, 2022, 1-14
- 199 Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma $\leq 5\text{ cm}$. 0
- 198 Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. 0
- 197 Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. 1
- 196 Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. 030089162211102
- 195 Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice. **2022**, 14, 1459-1469
- 194 Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review. 2
- 193 Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. 2

- 192 Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol.
- 191 Development and prognosis of hepatocellular carcinoma in patients with diabetes. 0
- 190 The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients. **2022**, 14, 1669 0
- 189 The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?. **2022**, 11, 4399 1
- 188 Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis.
- 187 How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?. 12,
- 186 Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. **2022**, 5, e2223511 0
- 185 Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients. **2022**, 58, 1015 1
- 184 Health Disparities in Chronic Liver Disease. 1
- 183 Advances of cancer-associated fibroblasts in liver cancer. **2022**, 10, 4
- 182 Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. **2022**, 14, 3892
- 181 Investigation of the long-term healing response of the liver to boiling histotripsy treatment in vivo. **2022**, 12, 0
- 180 Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). Volume 9, 811-821
- 179 Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. **2022**, 28, 3917-3933 1
- 178 Radiomics and nomogram of magnetic resonance imaging for preoperative prediction of microvascular invasion in small hepatocellular carcinoma. **2022**, 28, 4399-4416 1
- 177 Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. **2022**, 50, 030006052211152
- 176 The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients. **2022**, 14, 1812 0
- 175 Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study. **2022**, 10, 8535-8546

174	Targeting N7-Methylguanosine tRNA modification blocks hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. 2022 ,	0
173	The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. 12,	
172	Current Imaging Diagnosis of Hepatocellular Carcinoma. 2022 , 14, 3997	2
171	Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis. 9,	0
170	Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.	1
169	Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records.	
168	Multiarterial Phase Acquisition in Gadoteric Acid-Enhanced Liver MRI for the Detection of Hypervascular Hepatocellular Carcinoma in High-Risk Patients. Publish Ahead of Print,	1
167	Reply to three letters. 2022 ,	
166	What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. 2022 , 100578	0
165	Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance. 2022 , 17, e0274747	0
164	High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. 2022 , 28, 5217-5229	0
163	Surgical Management of Hepatocellular Carcinoma. 2022 , 131-145	0
162	Diagnosis and Evaluation of Hepatocellular Carcinoma. 2022 , 27-48	0
161	Sonazoid-versus SonoVue for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. 23,	0
160	Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. 2022 , 11, 5075	1
159	Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology. 2022 , 65, 2114-2117	0
158	Antitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of Apoptosis. 2022 , 68, 303-311	0
157	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. 2022 , 2022,	0

156	ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis. 12,	0
155	Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade. 2022 , 14, 4445	1
154	HCC Surveillance in Patients with NAFLD.	0
153	A Multiparametric Fusion Radiomics Signature Based on Contrast-Enhanced MRI for Predicting Early Recurrence of Hepatocellular Carcinoma. 2022 , 2022, 1-12	0
152	Hepatocellular carcinoma. 2022 ,	13
151	The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma. Volume 14, 2735-2748	0
150	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. 2022 , 14, 4473	2
149	Dynamic changes in cytokine profiles and their impact on tumour recurrence following thermal ablation in hepatocellular carcinoma.	0
148	Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma. 14, 1008-1025	0
147	Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study.	0
146	Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients: A Retrospective Observational Study. 2022 , 14, 4422	0
145	Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting the prognosis of hepatocellular carcinoma after radiofrequency ablation.	0
144	Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma. 2022 , 2022, 1-6	0
143	Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis b virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study. 2022 ,	0
142	Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma. 2022 , 22,	0
141	The expression profiles of circular RNAs and competing endogenous RNA networks in intrahepatic cholangiocarcinoma. 10,	0
140	The risk of hepatocellular carcinoma of the liver in non-alcoholic fatty liver disease: features of prevention and treatment. 2022 , 284-289	0
139	Feature analysis of computed tomographic signs of hepatocellular carcinoma in multiphase studies. 2022 , 23-28	0

138	Positive predictive value of LI-RADS US-3 observations: multivariable analysis of clinical and imaging features.	0
137	Re-Do Surgery for Hepatocellular Carcinoma: Indications and Results. 2023 , 147-154	0
136	Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. 2022 ,	0
135	Does hypointense HCC in the Hepatobiliary Phase at Gadoxetate-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis. 2022 ,	0
134	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). 2023 , 139-146	0
133	Specific imaging features indicate the clinical features of patients with hepatic perivascular epithelioid cell tumor by comparative analysis of CT and ultrasound imaging. 12,	0
132	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. 2022 , 28, 583-705	3
131	Liver Function How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. 2022 , 12, 1657	1
130	Indications for Surgery in Cirrhotic Patients. 2023 , 81-88	0
129	Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. 2023 , 183-190	0
128	IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro.	0
127	Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis. 2022 ,	0
126	Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. 12,	0
125	Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. 2022 , 12,	1
124	HCC Surveillance in NAFLD patients.	0
123	Methylation Biomarkers for Early Cancer Detection and Diagnosis: Current and Future Perspectives. 2022 ,	1
122	The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment. 2022 , 34, 1269-1276	0
121	The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma. 2022 , 22,	0

120	Hepatocellular Carcinoma in Primary Biliary Cholangitis. 2022 , 26, 691-704	0
119	Evaluation of HASTE T2 weighted image with reduced echo time for detecting focal liver lesions in patients at risk of developing hepatocellular carcinoma. 2022 , 110588	1
118	Radiomics nomogram for prediction of microvascular invasion in hepatocellular carcinoma based on MR imaging with Gd-EOB-DTPA. 12,	0
117	Liver transplantation and portal vein tumour thrombus: futile enterprise?. 2022 , 27, 312-319	0
116	Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection.	1
115	Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer. 12,	0
114	Low-dose nivolumab in advanced hepatocellular carcinoma. 2022 , 22,	1
113	Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma. 2022 , 22,	0
112	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. 2022 , 21, 153303382211173	0
111	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
110	Contrast-enhanced ultrasound for assessing blood flow modulation of hepatocellular carcinoma by hydralazine. 2022 ,	0
109	Hepatozelluläres Karzinom Screening und Surveillance. 2022 , 17, 387-392	0
108	Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI. 12,	0
107	Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. 2022 , 14,	1
106	Factors associated with nonadherence to surveillance for hepatocellular carcinoma among patients with hepatic C virus cirrhosis, 2000-2015. 2022 , 101, e31907	0
105	Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. 2022 , 14, 2571	0
104	Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial. 12,	0
103	Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection. 13,	0

- 102 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. ○
- 101 Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma. 14, 2380-2392 1
- 100 A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma. 2022, 41, ○
- 99 An overview: Management of patients with advanced hepatocellular carcinoma. 2022, 16, 405-425 ○
- 98 Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. 2022, 14, 5997 ○
- 97 An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. ○
- 96 The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients. 2023, 95, ○
- 95 Association and impact of SNPs in PNPLA3, TM6SF2 and MBOAT7 genes on prognosis factors of hepatocellular carcinoma with non-viral etiology. ○
- 94 Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: A large-scale real-world study. 2022, 1, 209-216 ○
- 93 Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. 2023, 15, 50 ○
- 92 Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. 2022, 10, 3202 1
- 91 A study of the clinical profile, predictors, prognostic features, and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis. 2022, 41, 533-543 ○
- 90 Barriers to Palliative Care in Hepatocellular Carcinoma: A Review of the Literature. ○
- 89 Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. 15, 1-18 ○
- 88 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Imaging Diagnosis of Hepatocellular Carcinoma: What's New?. 2023, 24, 1 ○
- 87 The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages. 2023, 15, 390 ○
- 86 Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis. 2023, Publish Ahead of Print, ○
- 85 Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥ 5 cm): A propensity score matching analysis. ○

84	Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development. 2023 , 12, 94	0
83	Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. 29, 286-309	0
82	Cirrhotic and non-cirrhotic huge hepatocellular carcinoma (≥10 cm): a comparative study of surgical management and follow-up treatment in a single institution. 2024 , 408,	0
81	Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. 2023 , 15, 508	0
80	Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. 13,	0
79	Transradial versus transfemoral approach for TACE: a retrospective study. 2023 , 23,	0
78	Preoperative prediction of early recurrence of HBV-related hepatocellular carcinoma (≤ 5 cm) by visceral adipose tissue index. 9,	0
77	A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. 2023 , 24, 1681	0
76	HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. 2022 , 101, e32390	0
75	Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.	1
74	Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. 2023 , 15, 625	0
73	Hydralazine-augmented contrast ultrasound imaging improves the detection of hepatocellular carcinoma.	0
72	Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. 2023 , 24, 2358	0
71	Clinical practice guidelines and real-life practice for hepatocellular carcinoma in Taiwan.	0
70	Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. 2023 ,	0
69	Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade. 2023 , 15, 753	1
68	Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence. 2023 , 12, 213	0
67	Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review. 24,	0

66	Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA. 2023 , 15, 817	1
65	Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study. 2023 , 18, e0267809	0
64	Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region.	1
63	The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance.	0
62	Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy.	0
61	Factors Associated with Unrecognized Cirrhosis in Patients with Hepatocellular Carcinoma.	0
60	Global epidemiology and genetics of hepatocellular carcinoma. 2023 ,	0
59	Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy. 2023 , 13, 397	0
58	Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. 2023 , 30, 3206-3216	0
57	Targeting a novel circITCH/miR-421/BTG1 axis is effective to suppress the malignant phenotypes in hepatocellular carcinoma (HCC) cells.	0
56	LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.	0
55	Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. 2023 , 70, 102362	0
54	Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. 13,	0
53	Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation.	0
52	Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis.	0
51	Subcentimeter Nodules with Diagnostic Hallmarks of Hepatocellular Carcinoma: Comparison of Pathological Features and Survival Outcomes with Nodules Measuring 1-2 cm. Volume 10, 169-180	0
50	CT/MRI Liver Imaging Reporting and Data System (LI-RADS): Standardization, Evidence, and Future Direction. 2023 , 84, 15	0
49	Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review. 2023 , 13, 625	0

- 48 Non-alcoholic fatty liver disease-related hepatocellular carcinoma. **2023**, 23, 127-142 ○
- 47 Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry in Liver Disease Patients. **2023**, ○
- 46 Short Half-Life of Des-β-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. **2023**, 13, 696 ○
- 45 HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. **2023**, 13, 360 ○
- 44 Elucidation of the Usefulness of Glypican-3, a Hepatocellular Carcinoma Biomarker, with the Fully Automated LUMIPULSE[®] System. **2023**, 6, 21-26 ○
- 43 Updates on Organoid Model for the Study of Liver Cancer. **2023**, 22, 153303382311540 ○
- 42 Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals. 13, ○
- 41 An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. **2023**, 11, 586 ○
- 40 Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. **2023**, ○
- 39 Adherence to LI-RADS and EASL high-risk population criteria: a systematic review. Publish Ahead of Print, ○
- 38 Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: Systematic review and meta-analysis. **2023**, ○
- 37 Current status and prospect of treatments for recurrent hepatocellular carcinoma. 15, 129-150 ○
- 36 Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin. 29, 1359-1373 ○
- 35 Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia. ○
- 34 The development and prospects of liver surgery. **2023**, 2, 100009 ○
- 33 Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder. **2023**, 40, ○
- 32 Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. ○
- 31 International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance. **2023**, ○

- 30 Clinical Outcomes of Radiofrequency Ablation Combined with Transarterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Non-hepatocellular Carcinoma Malignant Liver Tumors. **2023**, 8, 7-13 ○
- 29 Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel. **2023**, 32, 16-23 ○
- 28 Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. **2023**, 115, 102526 ○
- 27 External validation and improvement of the scoring system for predicting the prognosis in hepatocellular carcinoma after interventional therapy. 10, ○
- 26 Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response. ○
- 25 Development of a nurse-led decision counselling program for improving hepatocellular carcinoma screening: A typology-guided feasibility study. **2023**, 100215 ○
- 24 The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≥ 1.0 cm on gadoxetate disodium-enhanced MRI. ○
- 23 Imaging in Hepatocellular Carcinoma: What's New?. **2023**, ○
- 22 Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. **2023**, 29, 252-262 ○
- 21 The prime time for management of hepatocellular carcinoma in Hong Kong. **2023**, 29, 345-348 ○
- 20 Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. ○
- 19 Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. **2023**, 36, 251-266 ○
- 18 Comparative effectiveness of different hepatocellular carcinoma screening intervals or modalities: a systematic review and meta-analysis. Publish Ahead of Print, ○
- 17 Head-to-head comparison of Sonazoid and SonoVue in the diagnosis of hepatocellular carcinoma for patients at high risk. 13, ○
- 16 Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients. **2023**, 128, 393-401 ○
- 15 Correlation and efficacy of TACE combined with lenvatinib plus PD -1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. ○
- 14 Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study. **2023**, 23, 189-201 ○
- 13 Efficacy of Radiation Plus Transarterial Chemoembolization and Lenvatinib in Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. ○

- 12 Hepatocellular carcinoma: State of the art diagnostic imaging. 15, 56-68 ○
- 11 Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. **2023**, 7, ○
- 10 A Statistical Approach to the Diagnosis and Prediction of HCC Using CK19 and Glypican 3 Biomarkers. **2023**, 13, 1253 ○
- 9 Conclusions (multiparametric ultrasound for the work-up of chronic liver disease). **2024**, 237-242 ○
- 8 The role of positron emission tomography in the diagnosis and treatment of oncological diseases of the hepatobiliary system. **2022**, 13, ○
- 7 S3-Leitlinie Diagnostik und Therapie biliärer Karzinome [Langversion]. **2023**, 61, e92-e156 ○
- 6 OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma. ○
- 5 Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. **2023**, 13, 1442 ○
- 4 Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening. **2023**, 2023, 1-13 ○
- 3 Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study. **2023**, 23, ○
- 2 The Gray Zone: LR3, LR-M, and LR-TIV. ○
- 1 Optimal Treatment for Small HCC (<3 cm): Resection, Liver Transplantation, or Locoregional Therapy?. **2023**, 100781 ○